KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Assets: 2009-2025

Historic Other Non-Current Assets for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $1.7 billion.

  • Regeneron Pharmaceuticals' Other Non-Current Assets rose 60.41% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 60.41%. This contributed to the annual value of $1.1 billion for FY2024, which is 155.80% up from last year.
  • Regeneron Pharmaceuticals' Other Non-Current Assets amounted to $1.7 billion in Q3 2025, which was up 8.86% from $1.5 billion recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Other Non-Current Assets peaked at $1.7 billion during Q3 2025, and registered a low of $142.9 million during Q2 2021.
  • Moreover, its 3-year median value for Other Non-Current Assets was $993.8 million (2024), whereas its average is $894.8 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Other Non-Current Assets declined by 18.58% in 2021, and later soared by 196.28% in 2025.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Other Non-Current Assets stood at $216.1 million in 2021, then surged by 55.67% to $336.4 million in 2022, then surged by 32.02% to $444.1 million in 2023, then spiked by 155.80% to $1.1 billion in 2024, then skyrocketed by 60.41% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.4 billion during Q1 2025.